Financial Data and Key Metrics Changes - Total revenues increased to $13 million in Q4 2025 from $11.9 million in Q4 2024, a 10% increase primarily driven by manufacture and supply revenue growth [18][19] - Full year 2025 total revenues decreased to $44.5 million from $57.6 million in 2024, a decline of 22.5% due to the one-time recognition of deferred revenues in the prior year [19][26] - R&D expenses decreased to $3.2 million in Q4 2025 from $4.9 million in Q4 2024, and for the full year, R&D expenses decreased to $17.2 million from $20.3 million [20][21] - Selling, general and administrative expenses increased to $32.8 million in Q4 2025 from $16 million in Q4 2024, primarily due to higher legal expenses and commercial spending [22][23] - Net loss for Q4 2025 was $31.9 million, compared to a net loss of $17.1 million in Q4 2024 [24][26] - Cash and cash equivalents as of December 31, 2025, were $121.2 million, with a guidance for 2026 total revenue of $46 million to $50 million [28][29] Business Line Data and Key Metrics Changes - Manufacture and supply revenue increased to $12 million in Q4 2025 from $10.7 million in Q4 2024, driven by increases in Suboxone and Ondif revenues [19] - Full year manufacture and supply revenue increased slightly to $40.2 million from $40 million in 2024, primarily due to increases in Ondif revenues [20] Market Data and Key Metrics Changes - The overall allergy market grew by just over 9% in Q4 2025, with EpiPen and generic auto injectors growing by approximately 5% [13] - Over 90% of prescriptions remain with auto-injectors, indicating a strong market preference for medical devices [14] Company Strategy and Development Direction - The company is focused on launching Anaphylm, with plans to file in Europe and Canada by the end of the year and to meet with the U.K. Health Authority [11] - The commercial strategy includes launching with 75 sales representatives, 50% more than previously planned, to enhance market penetration [12][42] - The company is also prioritizing out-licensing activities for Libervant and exploring partnerships for Anaphylm in international markets [15][90] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's future, citing a clear path for Anaphylm's market entry and a strong clinical team [8][10] - The management highlighted the importance of capital access for the drug launch and noted the extension of a revenue sharing agreement with RTW [13][18] - The company anticipates a non-GAAP adjusted EBITDA loss of $30 million to $35 million for 2026, reflecting ongoing costs associated with Anaphylm's NDA resubmission and pre-commercial activities [29][30] Other Important Information - The company reached a settlement in a long-standing defamation lawsuit, which is expected to reduce distractions from the business [14] - The FDA's recent denial of a competitor's citizen petition was seen as a validation of the company's data package [64] Q&A Session Summary Question: Confirmation of Type A meeting with the FDA - The company confirmed that a Type A meeting request has been submitted and is expected to occur within 30 days [32][33] Question: Goals for the FDA meeting - The goals include ensuring alignment on executing the requested studies and clarifying any minor protocol modifications [32][34] Question: RTW agreement extension - The extension until June 30, 2027, was made for flexibility, and the terms of the agreement remain unchanged [39][40] Question: Sales force expansion rationale - The decision to increase sales reps was driven by the need for deeper market penetration and greater efficiency in reaching key physicians [42][44] Question: Future clinical development of AQST-108 - The company indicated that AQST-108's development will be prioritized after Anaphylm's resubmission, but both projects are linked [86][87] Question: Promotional campaign adjustments - The company is refining its launch plan but does not anticipate fundamental changes in messaging or strategy [82][83] Question: Updates on the citizen petition and AAAAI conference takeaways - The FDA denied a competitor's petition, validating the company's data, and feedback from the AAAAI conference indicated strong interest in Anaphylm [64][66]

Financial Data and Key Metrics Changes - Revenue for Q4 2025 increased by 21.4% year-over-year to RMB 1.7 billion, while full-year revenue grew by 35.0% to RMB 6.1 billion [6][7] - Net operating cash inflow reached RMB 416 million, a net increase of RMB 158 million year-over-year, reflecting improved operational quality and efficiency [7] - The company repurchased a total of RMB 670 million of shares, representing 12.8% of total outstanding shares [8] Business Line Data and Key Metrics Changes - Learning services contributed over 95% of net revenues, with academic tutoring and traditional learning services accounting for over 80% of total revenues [18][19] - In Q4, gross billings for academic tutoring services increased by over 30% year-over-year, while revenue grew by 45% [19] - Revenue from traditional business grew nearly 15% year-over-year, driven by operational efficiency gains [22] Market Data and Key Metrics Changes - The offline business has achieved clear economies of scale, with expectations for revenue to surpass several independently listed peers in the coming year [31] - User satisfaction and retention rates continue to improve, indicating a strengthening brand reputation in regional markets [32] Company Strategy and Development Direction - The company is focusing on profitable growth with AI capabilities as a core operational element, aiming to enhance business health and operational efficiency [6][9] - Strategic priorities for 2026 include calibrating growth pace, advancing product development, integrating technology, reinforcing talent strategy, and enhancing the business portfolio [9][11] - The company aims to build a comprehensive lifelong learning service platform, ensuring tailored solutions for learners at different developmental stages [11][12] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's resilience and ability to generate lasting value for shareholders, employees, users, and society [14] - The company anticipates total net revenue for Q1 2026 to be between RMB 1,578 million and RMB 1,598 million, representing a year-over-year increase of 5.7%-7.0% [26] Other Important Information - The deferred revenue balance rose by 23.0% year-over-year to RMB 2.6 billion, providing solid visibility for future revenue growth [18] - Cash equivalents and investments totaled RMB 4.0 billion, indicating strong financial health to support ongoing investments [25] Q&A Session Summary Question: Development of offline business and future plans - The offline business represents a clear second growth curve and is a top strategic priority, with expectations for revenue to surpass several peers [30][31] - The company has established a professional team for offline operations, which is crucial for scalable growth and effective execution [31] - The offline business is expected to achieve profitability at the school level this year and overall profitability next year [33]

Financial Data and Key Metrics Changes - For Q4, the company achieved identical sales without fuel growth of 2.4%, with a full-year growth of 2.9%, nearly doubling from 1.5% to 2.9% [7][12][20] - Earnings per share (EPS) grew by 9% for the full year, reaching $4.85, which was at the high end of expectations [7][25] - Adjusted EPS for Q4 was $1.28, reflecting a 12% increase compared to the previous year [25] Business Line Data and Key Metrics Changes - E-commerce sales grew by 20% in Q4, contributing to a $16 billion business, with profitability improvements expected as the business scales [16][19] - Pharmacy sales showed strength, although growth was impacted by the Inflation Reduction Act, contributing nearly 50 basis points less than in Q3 [20][21] - The company's private label brands, including Simple Truth and Private Selection, continued to outperform national brands, with over 1,100 new products introduced [15] Market Data and Key Metrics Changes - The company reported positive market share growth for the first time in the year during Q4, marking the strongest share performance since 2021 [7][14] - Food volumes improved, with grocery sales becoming a larger portion of the sales mix, indicating a positive trend for future growth [20][21] Company Strategy and Development Direction - The company is focused on enhancing customer experience, simplifying operations, and investing in e-commerce and AI capabilities [8][10][19] - Plans include expanding new store openings by 30% in 2026 and entering new markets such as Jacksonville and Kansas City [11][30] - The company aims to balance price investments with margin management, ensuring competitive pricing while maintaining profitability [14][30] Management's Comments on Operating Environment and Future Outlook - Management noted that customers remain focused on value, and the company is committed to investing in price to meet customer expectations [12][19] - The outlook for 2026 includes expected identical sales without fuel growth in the range of 1%-2%, with a headwind from the Inflation Reduction Act [28][30] - Management expressed confidence in the company's ability to achieve cost savings and improve operational efficiencies, which will support future growth [24][31] Other Important Information - The company completed a $7.5 billion share repurchase authorization, with an additional $2 billion approved for future repurchases [26][27] - Capital expenditures are expected to be in the range of $3.8 billion-$4 billion, with a focus on new store growth and technology investments [33] Q&A Session Summary Question: Can you discuss initiatives to accelerate top-line growth? - Management acknowledged the need for further price investments and highlighted opportunities in sourcing and procurement [46][48] Question: What are the quantifiable targets for AI's impact on customer experience? - Management sees AI as a significant opportunity, with ongoing investments aimed at improving operations and customer experience [50][51] Question: Can you contextualize the dollar level of investment made in Q4? - Management indicated that significant investments were made to improve value perception and market share, with a focus on balancing margins [60][62] Question: What is the outlook for free cash flow and capital expenditures? - Management explained that free cash flow guidance reflects strong performance but anticipates some timing-related reversals impacting future guidance [66][68] Question: What opportunities do you see regarding the in-store experience? - Management emphasized the importance of fresh offerings and the need to improve execution across stores to drive sales and market share [73][76]

Aquestive Therapeutics (NasdaqGM:AQST) Q4 2025 Earnings call March 05, 2026 08:00 AM ET Speaker8Good day, and thank you for standing by. Welcome to Aquestive Therapeutics fourth quarter 2025 conference call. At this time, all participants are on a listen only mode. After the speaker presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star one one on your telephone. You will then hear an automated message advising your hand is raised. Please ...

Financial Data and Key Metrics Changes - Kroger reported identical sales without fuel growth of 2.4% in Q4, with a full-year growth of 2.9%, nearly doubling from 1.5% to 2.9% year-over-year [6][12][19] - Earnings per share (EPS) grew by 9% for the full year, reaching $4.85, which was at the high end of expectations [6][24] - Adjusted EPS for Q4 was $1.28, reflecting a 12% increase compared to the previous year [24] Business Line Data and Key Metrics Changes - E-commerce sales grew by 20% in Q4, contributing to a $16 billion business, with profitability improvements expected as the business scales [15][40] - Pharmacy sales showed strength, although growth was impacted by the Inflation Reduction Act, leading to a shift from brand to generic medications [19][20] - The company's private label brands, including Simple Truth and Private Selection, continued to outperform national brands, with over 1,100 new products introduced [14] Market Data and Key Metrics Changes - Kroger achieved positive market share growth for the first time in the year, with improved trends in both Q4 and the full year [6][13] - Food volumes improved, with grocery sales becoming a larger portion of the sales mix, indicating a positive trend for future growth [12][19] Company Strategy and Development Direction - The company is focused on enhancing customer experience, simplifying operations, and investing in e-commerce and AI capabilities [9][10][34] - Plans include expanding new store openings by 30% in 2026 and entering new markets such as Jacksonville and Kansas City [11][30] - Kroger aims to balance price investments with margin management, ensuring competitive pricing while maintaining profitability [13][24] Management's Comments on Operating Environment and Future Outlook - Management noted that customers remain focused on value, and the company is committed to investing in price to meet customer expectations [12][18] - The outlook for 2026 includes expected identical sales growth without fuel in the range of 1%-2%, with inflation impacts considered [27][30] - Management expressed confidence in the company's ability to achieve cost savings and improve operational efficiencies [23][31] Other Important Information - The company completed a $7.5 billion share repurchase authorization, with an additional $2 billion approved for future repurchases [25][26] - Kroger is investing in technology and AI to enhance customer experience and drive productivity [34] Q&A Session Summary Question: Initial assessment of sales growth initiatives - Management acknowledged the need for further price investments and highlighted existing strengths in fresh products and e-commerce [48][50] Question: AI's impact on customer experience and productivity - Management sees AI as a significant opportunity, with ongoing investments aimed at improving operations and customer engagement [52][54] Question: Investment levels to stabilize market share - Management indicated that significant investments have been made in promotions and pricing to improve value perception while balancing margins [61][64] Question: Free cash flow outlook and CapEx distribution - Management explained that strong cash flow performance was driven by working capital initiatives, with a focus on prioritizing investments in new stores and supply chain [68][70] Question: Opportunities for in-store experience improvements - Management emphasized the importance of fresh offerings and consistent execution across stores, with a focus on price and customer experience [76][80]

Financial Data and Key Metrics Changes - Revenue for Q4 2025 increased by 21.4% year-over-year to RMB 1.7 billion, while full-year revenue grew by 35.0% to RMB 6.1 billion [6][7] - Net operating cash inflow reached RMB 964.8 million, a 23.1% increase year-over-year, reflecting improved operational quality and efficiency [24] - The company repurchased shares totaling RMB 670 million, representing 12.8% of total outstanding shares [8] Business Line Data and Key Metrics Changes - Learning services contributed over 95% of net revenues, with academic tutoring and traditional learning services accounting for over 80% of total revenues [17] - In Q4, gross billings for academic tutoring services increased by over 30% year-over-year, while revenue grew by 45% [18] - Revenue from traditional business grew nearly 15% year-over-year, driven by operational efficiency gains [21] Market Data and Key Metrics Changes - The deferred revenue balance rose by 23.0% year-over-year to RMB 2.6 billion, providing visibility for future revenue growth [17] - The company expects total net revenue for Q1 2026 to be between RMB 1,578 million and RMB 1,598 million, representing a year-over-year increase of 5.7%-7.0% [25] Company Strategy and Development Direction - The company is focusing on profitable growth with AI capabilities as a core operational element, aiming to enhance business health and operational efficiency [6][9] - Strategic priorities for 2026 include optimizing growth pace, product development, technology integration, talent strategy, and enhancing the business portfolio [9][11] - The company aims to build a comprehensive lifelong learning service platform, integrating product formats and delivery models [12] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's resilience and ability to generate long-term value for shareholders, emphasizing disciplined management and risk control [13] - The company is committed to enhancing user experience and learning outcomes, transitioning from skill-oriented growth to a more efficiency-led model [16] Other Important Information - The company has established a staged growth roadmap that provides visibility into future development, supported by solid growth in core businesses and strategic initiatives [15] - The integration of online and offline services is seen as a critical step in building long-term competitive advantages [30] Q&A Session Summary Question: Development of offline business and future plans - Management highlighted the offline business as a strategic priority, achieving clear economies of scale and expecting revenue to surpass several independently listed peers [30][32] - The offline business has established a solid foundation with improved user satisfaction and retention rates, transitioning from a pure online service provider to a fully integrated platform [32][33]

Financial Data and Key Metrics Changes - The Prada Group reported net revenues of EUR 5.7 billion, an increase of 9% compared to fiscal year 2024 at constant FX, and an organic growth of 8% year-over-year, marking the fifth consecutive year of growth at the group level [18][19] - Retail sales totaled EUR 5.1 billion, up 8% organically versus fiscal year 2024, and up 28% versus fiscal year 2023 at constant FX [19] - EBIT adjusted reached EUR 1.32 billion with a margin of 23.2%, including the dilutive impact of Versace [19][25] - Net income increased by 2% to EUR 852 million compared to fiscal year 2024 [25] Business Line Data and Key Metrics Changes - Prada brand closed the year at -1%, with Q4 showing sequential improvement, particularly supported by Mainland China, Korea, Japan, and the Americas [21] - Miu Miu retail sales grew by 35% to reach EUR 1.6 billion, with Q4 sales up by 20% against a high comp of +84% in 2024 [22][23] - Church's brand continued on a positive trajectory driven by like-for-like sales [23] Market Data and Key Metrics Changes - Asia Pacific region showed growth of +11%, +10% organic, with Q4 performance in line with Q3 [24] - Europe reported a growth of 5% over the year, with softer trends in the second half due to strong multi-year comps and lower tourism [24] - The Americas experienced consistent double-digit growth, with sales up 18%, +15% organic, driven by local demand [24] - Japan delivered growth of +3%, with improvements in Q4 driven by solid local demand and increased traveler flows [24] Company Strategy and Development Direction - The company is focused on enhancing digital capabilities and hospitality standards, investing in strategic digital plans and AI tools to improve product value and customer engagement [5][6] - The acquisition of Versace is seen as a new chapter, with plans for creative leadership changes and a focus on quality and full-price sales [28][30] - The company aims to maintain a steady profitability while investing in brand desirability and awareness [6][19] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenging operating environment in 2025 but expressed confidence in the company's ability to navigate through it, expecting solid performance in 2026 [3][9] - The first half of 2026 is anticipated to be more challenging for Prada, with expectations of single-digit growth, while Miu Miu is expected to achieve double-digit growth if conditions allow [9][44] - Management emphasized the importance of agility and efficiency in the current market landscape [40] Other Important Information - The company completed the acquisition of Versace on December 2, 2025, consolidating one month of contribution from the brand into its financials [18] - CapEx for fiscal year 2025 was EUR 620 million, with continued investments in retail and technology [26] - The board proposed a dividend per share of EUR 0.166, maintaining a stable payout ratio of 50% [27] Q&A Session Summary Question: Expectations for Prada's growth in 2026 - Management refrained from providing specific guidance but indicated that if conditions are favorable, double-digit growth for Miu Miu is possible [44][45] Question: Versace's team and store rationalization - The team is a hybrid of internal and external hires, with a focus on full-price retail and rationalization of the outlet channel [50][51] Question: Revenue contraction for Versace - Management confirmed expectations for mid-single-digit contraction at constant FX for Versace, with efforts to limit operating losses to a double-digit figure [59][60] Question: Store openings and closures - Prada expects to close more stores than it opens in 2026, while Miu Miu plans to add 5-10 stores [80] Question: Prada brand cluster trends - Significant improvement in the Chinese cluster, while European demand remained resilient, and North American sales showed positive growth [86]

Financial Data and Key Metrics Changes - Revenue for Q4 2025 increased by 118% to $1.7 million compared to $0.8 million in the prior year, primarily due to post-acquisition contributions [20][21] - GAAP net loss for Q4 was $1.5 million or $0.04 per share, while non-GAAP net loss was $6.9 million or $0.16 per share, with significant differences attributed to non-cash gains and acquisition-related expenses [23][24] - Cash equivalents and marketable securities as of December 31, 2025, were approximately $47 million, with a net cash burn rate of about $10 million for the quarter [24][25] Business Line Data and Key Metrics Changes - The company has transitioned from a development-stage AI company to a vertically integrated industrial and defense platform, with significant revenue growth expected in 2026 [5][8] - Backlog increased from approximately $13.5 million at the end of 2025 to nearly $18 million midway through Q1 2026, reflecting new contract wins [5][25] Market Data and Key Metrics Changes - The company is actively pursuing opportunities in both defense and commercial sectors, with expectations of organic growth across all business units [30][35] - The defense sector is seeing increased interest in collaborative swarming and autonomy technologies, which the company is well-positioned to capitalize on [31][32] Company Strategy and Development Direction - The company aims to prove its integrated model works at scale in 2026, focusing on converting backlog into revenue and monetizing development programs [18][19] - The strategic focus includes expanding capabilities in air, space, land, and maritime domains, with a strong emphasis on AI-driven technologies [16][19] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth trajectory, citing a favorable operating environment and increased inquiries from potential customers [61] - The company anticipates that 2026 will mark the first full year of operations reflecting its structural transformation into a more integrated entity [19] Other Important Information - The company has strengthened its intellectual property portfolio with new patents related to decentralized swarming architectures and AI technologies [17] - Management highlighted the importance of educating potential customers about the unique capabilities of their AI and swarming technologies [58][59] Q&A Session Summary Question: Expectations for growth drivers in 2026 - Management expects organic growth across all business areas, including new customer relationships and contracts, but did not provide specific revenue breakdowns [30] Question: Insights on missile contracts and future opportunities - The company is involved in both new missile efforts and existing large missile programs, focusing on innovation and AI integration [38] Question: Clarification on cash usage expectations - The expected cash usage of $8 million-$9 million is based on operational cash flow, excluding other cash inflows [40] Question: R&D priorities for 2026 - Top R&D priorities include advancements in UAV platforms, SwarmOS, and IQ, aligned with government contracts [62]

Financial Data and Key Metrics Changes - In Q4 2025, net revenues increased by 20% year-over-year to RMB 123.5 million, exceeding previous guidance [3][16] - Revenues from package tours grew by 35% year-over-year to RMB 102.1 million, accounting for 83% of total net revenues [16] - For the full year 2025, net revenues reached RMB 578 million, a 13% year-over-year increase, with package tour revenues up 21% to RMB 493.5 million [19][20] - Gross profit for Q4 2025 was RMB 17 million, nearly unchanged from Q4 2024, while full year gross profit was RMB 335 million, down 6% year-over-year [17][20] - Net income attributable to ordinary shareholders was RMB 1.5 million in Q4 2025 and RMB 31.1 million for the full year [18][20] Business Line Data and Key Metrics Changes - Package tours and self-guided tours were the primary growth drivers, with organized tours contributing significantly to revenue increases [19] - Other revenues decreased by 21% year-over-year in Q4 2025, primarily due to a decline in merchandise sales [16] - Transaction volume from corporate clients increased by over 20% year-over-year in Q4 2025, indicating strong demand in that segment [12][13] Market Data and Key Metrics Changes - The travel market showed healthy growth, supported by extended national holidays and favorable policies that stimulated domestic travel demand [4] - Live streaming channels contributed over 15% to total transaction volume in 2025, up from approximately 10% in 2024, reflecting a growing trend in customer engagement [10] Company Strategy and Development Direction - The company adopted a proactive product strategy in 2025, targeting distinct customer segments and offering a tailored portfolio [4] - A long-term shareholder return plan of up to $50 million was announced, reflecting confidence in the travel industry's long-term outlook [3] - The company plans to continue expanding self-guided tour products and enhancing service quality through technology and partnerships [10][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term growth of the travel industry, citing increased demand for both domestic and international travel [4] - The company aims to refine products and services while diversifying channels to support stable growth in the coming years [15] Other Important Information - The company has over 400 offline stores nationwide, with transaction volume from these stores increasing by nearly 20% year-over-year [12] - Cash and cash equivalents as of December 31, 2025, totaled RMB 1.1 billion, indicating a strong liquidity position [18] Q&A Session Summary - There were no questions during the Q&A session, indicating a lack of immediate inquiries from analysts or investors [22]

Financial Data and Key Metrics Changes - Kura Oncology reported net product revenue of $2.1 million from Komzifti sales in Q4 2025, compared to none in Q4 2024 [16] - Collaboration revenue from the partnership with Kyowa Kirin was $15.2 million, down from $53.9 million in the same period in 2024 [16] - Research and development expenses increased to $64.4 million from $52.3 million in Q4 2024, driven by ziftomenib combination trials [16] - Sales, general, and administrative expenses rose to $39.1 million from $24.1 million in Q4 2024, attributed to the commercial launch of Komzifti [17] - The net loss for Q4 2025 was $81 million, compared to a net loss of $19.2 million in Q4 2024 [17] - Cash equivalents and short-term investments as of December 31, 2025, were $667.2 million, down from $727.4 million at the end of 2024 [17] Business Line Data and Key Metrics Changes - Komzifti generated $2.1 million in net product revenue shortly after its launch, indicating a strong start [3] - The initial U.S. market for NPM1-mutated relapse refractory AML is estimated at approximately $350 million to $400 million annually [10] - Kura anticipates a total U.S. opportunity across relapsed refractory and frontline AML of approximately $7 billion [4] Market Data and Key Metrics Changes - Prescription trends for Komzifti are strong, with positive feedback from physicians and pharmacists regarding its clinical activity and ease of use [7] - Approximately 84% of private payers established coverage for Komzifti within 90 days of approval, surpassing industry benchmarks [9] - Certain blue plans are requiring patients to use Komzifti before allowing coverage for other approved menin inhibitors, indicating a competitive advantage [9] Company Strategy and Development Direction - Kura's strategy focuses on executing commercially, expanding development of ziftomenib across the AML treatment continuum, and advancing a pipeline with meaningful catalysts in 2026 [5] - The company aims to position ziftomenib as a foundational combination partner in AML, including with FLT3 inhibitors and standard backbone regimens [4] - Kura is advancing a focused solid tumor strategy alongside its AML initiatives [4] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strong early launch of Komzifti and its potential to establish leadership in the menin inhibitor class [6] - The company is focused on quarter-over-quarter growth, net revenue, and new patient starts, with plans to provide additional metrics to track progress [10] - Management highlighted the importance of combination therapies in driving better outcomes for patients and gaining market share [42] Other Important Information - Komzifti is now listed in the FDA's Orange Book with patent protection through July 2044, enhancing the long-term value of the franchise [4] - Kura expects to provide guidance for collaboration revenue of $45 million to $55 million in 2026, with anticipated milestones of $180 million under the collaboration agreement with Kyowa Kirin [18] Q&A Session Summary Question: Can you provide more information about the step editing policy from payers? - Management noted that some payers are recommending Komzifti before other menin inhibitors based on its differentiated profile, particularly its cost predictability and safety [25][26] Question: Can you comment on patient demand versus revenue generation? - Management indicated that the launch has been strong, with positive feedback from physicians and expectations for increased patient demand as more data becomes available [33] Question: What do you see as the biggest hurdle for Komzifti to gain market share in 2026? - Management identified the need to get incident patients onto therapy as a key challenge, with no significant payer hurdles reported [40] Question: How do you plan to maximize the FLT3 opportunity? - Management emphasized the importance of combining ziftomenib with FLT3 inhibitors to capture a significant portion of the AML market, as FLT3 mutations represent a large patient population [64] Question: What are the expectations for duration of therapy with Komzifti? - Management stated that while it is early to provide specific data, they expect patients to be treated for up to six months, with ongoing assessments of treatment duration as more data becomes available [87]